Air Liquide strategy in home healthcare, shares supported by Buy consensus

Air Liquide enters late June with fresh contracts in Spanish home healthcare and a solid Buy-rated analyst consensus on Euronext Paris, while the stock trades in the upper half of its 52-week range.

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-22, 16:16.

Air Liquide (FR0000120073) underpins its long-term growth profile with new business in European home healthcare while its shares trade on Euronext Paris in the upper part of their 52-week range. The industrial gases group remains a heavyweight in the CAC 40 alongside peers such as Linde and Holcim, supported by constructive analyst views on its strategy.

New Spanish homecare contracts strengthen footprint

On 17 June 2026, Air Liquide announced that it had been awarded what it calls its largest-ever contract in Spain to care for around 90,000 patients with chronic respiratory diseases at home, marking a clear expansion of its Iberian healthcare footprint.Air Liquide IR release on Spanish homecare contract The four-year agreement covers a wide range of pathologies including sleep apnea, chronic obstructive pulmonary disease and other long-term respiratory disorders, consolidating the company’s position as a leading homecare provider in Europe.

In the same communication cycle, the group highlighted the deployment of its Access Oxygen program in Madagascar, designed to improve access to medical oxygen in remote rural areas by installing production and distribution units close to patients.Air Liquide IR note on Access Oxygen in Madagascar These initiatives align with Air Liquide’s strategic emphasis on healthcare as a structural growth pillar alongside its core industrial gases activities, with management previously flagging healthcare as a key contributor to resilient cash flows.

Analyst consensus remains predominantly Buy

Analyst sentiment on Air Liquide remains clearly constructive heading into the estimated half-year earnings date of 28 July 2026, with most houses recommending investors maintain exposure to the stock.Investing.com Air Liquide consensus overview According to consensus data compiled by Investing.com, 20 analysts currently follow Air Liquide, of which 17 rate the stock Buy, 2 suggest Hold and only 1 advises Sell, pointing to broad confidence in the group’s strategy and balance sheet.

The same compilation places the average 12-month price target at roughly 181 euros, with individual expectations spanning approximately from 153 to 200 euros per share.Investing.com Air Liquide target range data Based on that average target, the implied upside potential versus a reference price in the mid-160-euro area stands close to 10 percent, situating the stock as a core defensive name in the European chemicals and industrial gases sector.

How Air Liquide makes its money

Air Liquide generates revenue primarily by supplying industrial and medical gases such as oxygen, nitrogen, hydrogen and specialty gases, alongside related equipment and services, to clients in sectors ranging from steel and chemicals to electronics and healthcare.Air Liquide business overview Its Healthcare business, which includes home respiratory services, hospital oxygen and medical gases, has grown into a sizeable contributor, helping to stabilize earnings through long-term contracts and recurring demand from hospitals and homecare patients.

Where the Air Liquide shares trade today

The Air Liquide shares (FR0000120073) most recently traded on Euronext Paris at around 165.00 euros as of 2026-06-18, 17:35, with the stock firmly anchored in the CAC 40 benchmark index.

Key data on the Air Liquide shares

• Company: Air Liquide S.A.
• ISIN: FR0000120073
• WKN: 850133
• Ticker: AI
• Trading venue: Euronext Paris
• Price (as of 2026-06-18, 17:35): 165.00 EUR
• Market cap: around 96 billion EUR (as of 2026-06-18)
• Sector / industry: Industrial gases / basic materials
• Index membership: CAC 40
• Next earnings date: 2026-07-28 (estimate)

This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any financial instrument. Investors should conduct their own research or consult a qualified financial advisor before making investment decisions.